Illinois is currently home to 2669 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
NCT03999983
Recruiting
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/10/2025
Locations: Northwestern Medicine Regional Medical Group, Winfield, Illinois
Conditions: Vertebral Artery Stenosis
Register for Updates
GYNecologic Cancer-Related COGnitive Impairment
NCT06662435
Recruiting
The goal of this study is to test a home-based and patient-tailored cognitive training intervention among gynecologic cancer patients who have completed chemotherapy and who have experienced cancer-related cognitive impairment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer
Register for Updates
Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics
NCT06401577
Recruiting
The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the m... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/07/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Acute Pancreatitis
Register for Updates
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
NCT05026749
Recruiting
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Gender:
ALL
Ages:
Between 3 days and 2 years
Trial Updated:
02/07/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Feasibility Testing a Meditation App for Professionals Working With Youth in the Legal System
NCT06555172
Recruiting
This feasibility clinical trial aims to assess the feasibility of implementing a 1-month app-based meditation program with officers in the juvenile legal system and other professionals working directly with legal-involved youth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Anxiety, Depression, Burnout, Professional, Emotion Regulation
Register for Updates
Dupilumab in the Treatment of Pediatric Alopecia Areata
NCT05866562
Recruiting
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants completing through Week 48. All subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥200 and/or have personal and/o... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/06/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Alopecia Areata
Register for Updates
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: St. Jude Midwest Affiliate - Peoria, Peoria, Illinois
Conditions: Hodgkin Lymphoma
Register for Updates
Hypofractionation (Radiation) Trial for Multiple Myeloma
NCT06270888
Recruiting
This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypofractionation) for pelvic radiation is safe for multiple myeloma. Because participants in this study will receive a shortened radiation course, each daily treatment dose that is delivered would be slig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: The University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Multiple Myeloma
Register for Updates
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Advocate Health System, Downers Grove, Illinois
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Register for Updates
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
NCT05786417
Recruiting
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: Cook County Health, Chicago, Illinois
Conditions: Angina, Stable Ischemic Heart Disease
Register for Updates
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT05726292
Recruiting
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
NCT05204888
Recruiting
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/05/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: COPD
Register for Updates